Antibody-drug conjugates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 34, 2013, Pages 13695-

  Ornes, Stephen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BRENTUXIMAB VEDOTIN; CETUXIMAB; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; TOXIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTIBODY CONJUGATE; CAC10-VCMMAE; DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DRUG CONJUGATION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CELL KILLING; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; METASTATIC COLORECTAL CANCER; NOTE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STOMACH CANCER; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; TRENDS;

ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; PHARMACEUTICAL PREPARATIONS;

EID: 84882784611     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314120110     Document Type: Note

References (4)

1. FDA (2011) FDA news release: "FDA approves Adcetris to treat two types of lymphoma." Available at www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm268781.htm. Accessed September 15, 2012.
2. Younes A, et al. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30(18):2183-2189.
3. Verma S, et al.; EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783-1791.
4. FDA (2010) FDA news Release: "Pfizer voluntarily withdraws cancer treatment Mylotarg from U.S. market." Available at www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm216448.htm. Accessed September 15, 2012.